Assay of the antiangiogenic compound TNP-470, and one of its metabolites, AGM-1883, by reversed-phase high-performance liquid chromatography in plasma

William D. Figg*, Herman J.C. Yeh, Alain Thibault, James M. Pluda, Fumio Itoh, Robert Yarchoan, Michael R. Cooper

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

This paper describes a reversed-phase, high-performance liquid chromatographic (HPLC) method for the isolation, detection, and quantification of TNP-470 (I) and one of its active metabolites, AGM-1883 (II), from plasma. These compounds are initially extracted from plasma with an organic solvent and then separated from one another on a C18 column. Those fractions eluting from the C18 column and containing either I or II are then derivatized through their epoxide moieties with sodium 8-quinolinethiolate (SQT). This derivatization produces fluorescent species that are isolated and quantified by a second reversed-phase HPLC analysis. The assay yields a lower limit of reliable quantification of 2.5 ng/ml and is linear to a concentration at least as high as 160 ng/ml. The inter-assay percent coefficient of variation is less than 18%.

Original languageEnglish
Pages (from-to)187-194
Number of pages8
JournalJournal of Chromatography B: Biomedical Sciences and Applications
Volume652
Issue number2
DOIs
StatePublished - 11 Feb 1994
Externally publishedYes

Fingerprint

Dive into the research topics of 'Assay of the antiangiogenic compound TNP-470, and one of its metabolites, AGM-1883, by reversed-phase high-performance liquid chromatography in plasma'. Together they form a unique fingerprint.

Cite this